Table 4.
Association of combined expression of HIVEP3 and SOX9 protein with the conventional clinicopathological characteristics in 98 patients with prostate cancer
| Clinical features | Case number | HIVEP3 and SOX9 expression (n)
|
P-value | ||
|---|---|---|---|---|---|
| HIVEP3(−) SOX9(−) | HIVEP3(+) SOX9(+) | HIVEP3(+) SOX9(−)/HIVEP3(−) SOX9(+) | |||
| Age (years) | |||||
| <60 | 60 | 23 | 20 | 17 | 0.490 |
| ≥60 | 38 | 15 | 16 | 7 | |
| Serum PSA levels (ng/mL) | |||||
| <4 | 12 | 5 | 4 | 3 | 0.938 |
| ≥4 | 86 | 32 | 33 | 21 | |
| Gleason score | |||||
| <8 | 87 | 35 | 31 | 21 | 0.329 |
| ≥8 | 11 | 2 | 6 | 3 | |
| Clinical stage | |||||
| <T2A | 59 | 19 | 28 | 12 | 0.051 |
| ≥T2A | 39 | 18 | 9 | 12 | |
| Metastasis | |||||
| No | 93 | 35 | 34 | 24 | 0.370 |
| Yes | 5 | 2 | 3 | 0 | |
| PSA failure | |||||
| No | 80 | 35 | 26 | 19 | 0.024 |
| Yes | 18 | 2 | 11 | 5 | |
Note: Bold P-values are statistically significant.
Abbreviation: PSA, prostate-specific antigen.